All News
Best Treatments for COVID-Related MIS-C
The RECOVERY trial focused on pediatric MIS-C patients treated with immunomodulators and anti-cytokine therapy demonstrated the benefits of first-line therapy with intravenous methylprednisolone or second-line tocilizumab in children refractory to initial treatment.
Read Article
New therapeutic approach for the treatment of sarcoidosis
d
Eureka Alert!
A research team led by Georg Stary (Medical University of Vienna and CeMM) has identified a new approach to treating the inflammatory disease sarcoidosis. In a clinical study, the inhibition of a specific signaling pathway showed clear success in the treatment of granulomas in the skin. This opens up new therapeutic paths for sarcoidosis and similar inflammatory diseases. The results were recently published in the journal Lancet Rheumatology.
Read Article
ACR Applauds Prior Authorization Rule
d
ACR
The American College of Rheumatology (ACR), on behalf of over 9,100 rheumatologists and rheumatology professional team members, applauds the Centers for Medicare and Medicaid Services (CMS) for finalizing its Advancing Interoperability and Improving Prior Authorization Processes for Medicare Adva
Read Article
Meta-analysis of 35 RCTs (>20K pts) with inflammatory skin disorders shows that w/ short-term (<5 mos) use JAK inhibitors do not significantly increase risk of all-cause mortality (OR, 0.83; 0.44-1.57), MACE, or VTE (OR, 0.52; 0.26-1.04). https://t.co/zBlcZ02QqQ https://t.co/cXjswVS9lF
Dr. John Cush RheumNow ( View Tweet)
Microbiome study of 16 SLE pts (44 fecal samples) shows that blooms of Ruminococcus gnavus pathobiont was assoc w/ lupus flares and may be the drivers of clinical of relapsing lupus disease https://t.co/OXA4L6kG4p https://t.co/zXX7ZfWik1
Dr. John Cush RheumNow ( View Tweet)
2019 NHIS chronic pain study shows signif disparity in nonpharmacologic & integrative medicine (IHM) use by populations. More IHM with city living, higher income & education, widespread pains. Less IHM w/ elderly, males, Blacks, opioid use, depression https://t.co/uoOyQBXTmy https://t.co/yTTVc5zljG
Dr. John Cush RheumNow ( View Tweet)
Join us this weekend! More than 25 sessions on topics ranging from spondyloarthritis, PsA, vasculitis and lupus to JAK inhibitors, RA, artificial intelligence and myositis. CME and MOC offered. Learn more about our program and registration options today!
https://t.co/6uWDDIUnvA https://t.co/aWk4IKZYC4
Links:
Dr. John Cush RheumNow ( View Tweet)
ACR Applauds Prior Authorization Rule
The ACR applauds the CMS for finalizing its Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations rule recently.
https://t.co/ZVPl2bUT3g https://t.co/ynynH0A8XN
Dr. John Cush RheumNow ( View Tweet)
Severe Hypocalcemia Risk w/Denosumab and CKD Patients
On 1/19 the FDA issued a Drug Safety Communication about the risk of severe hypocalcemia in CKD patients taking denosumab for osteoporosis.
https://t.co/VPpIZBZQkm https://t.co/yxFYn1ob5A
Dr. John Cush RheumNow ( View Tweet)
What do you know about monogenic and polygenic autoinflammatory diseases? Join Drs Liebowitz and Mehta as they review the challenges of these conditions. https://t.co/z0mTZEwFkP https://t.co/LAxl2eFZKR
Links:
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - RA, SSZ, & MI
RA with a myocardial inflarction - which DMARD?
https://t.co/9o83xedJ3j https://t.co/P5jmZAZ9rt
Dr. John Cush RheumNow ( View Tweet)
Join us this weekend! More than 25 sessions on topics ranging from spondyloarthritis, PsA, vasculitis and lupus to JAK inhibitors, RA, artificial intelligence and myositis. CME and MOC offered. Learn more about our program and registration options today!
https://t.co/Iac2T2Kohs https://t.co/zu1WJLOcmh
Links:
Dr. John Cush RheumNow ( View Tweet)
Methotrexate Nodulosis
How good (or not) are rheumatologists and what to do about MTX nodulosis?
https://t.co/Ot9UfpH68N https://t.co/JQ2AtuE7NV
Dr. John Cush RheumNow ( View Tweet)
11-yr French study of #RA Pregnancies: more adverse Preg outcomes in RA, esp w/ active Dz. 11.8K RA vs 10.4 million non-RA Pregs. 75% live births in RA. RA had more preterm(aOR 1.84), low birth wt (1.65), C-Sect (1.46), hospz (1.30), & prematurity (2.02)https://t.co/v9CmiPkIBG https://t.co/S0siiuG0oZ
Dr. John Cush RheumNow ( View Tweet)
Mexico survey of 250 RA pts -- 92% used complementary (CAM) therapies - mostly: herbals (65%), homeopathy (64%), cannabis derivatives (51%). Poor DMARD adherence assoc w/ age (p=0.019), comorbidities (p=0.047), CAM use (p = 0.042) (OR 2.84) https://t.co/EGxyIVCMnk https://t.co/jjF5cH53we
Dr. John Cush RheumNow ( View Tweet)
FDA Safety Warning: denosumab now has a Boxed Warning for risk of severe hypocalcemia in CKD pts taking Prolia (usually seen 2-10 wks post injx). Pts may or may not be symptomatic. CKD pts should have Ca and Creatinine monitored. https://t.co/tGiG35cOnv https://t.co/ITOZneGKtb
Dr. John Cush RheumNow ( View Tweet)
Rheumatologists and the Early Diagnosis of Spondyloarthritis
SPACE study of adults referred to rheumatology with less than 2 years of chronic back pain (CBP), shows that only one-third can be reliably diagnosed with axial spondyloarthritis (axSpA).
https://t.co/EwrrunyZs7. https://t.co/T0OqlsuU2P
Dr. John Cush RheumNow ( View Tweet)
Rheumatologists: What is your preferred MOA/Drug in treating Psoriatic Arthritis?
Dr. John Cush RheumNow ( View Tweet)
Rituximab Efficacy in MAINRITSAN Long-Term Studies
https://t.co/z16uMDihV4 https://t.co/BaWFcwDbYL
Dr. John Cush RheumNow ( View Tweet)
Sodium Channels, Carbemazepine and Osteoarthritis Progression
A study published in Nature suggests that therapies affecting sodium channels could be employed to treat osteoarthritis.
https://t.co/hmzKsgb3gA https://t.co/WVgk8nD4ne
Dr. John Cush RheumNow ( View Tweet)